Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 3
1(33.3%)
3Total
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05096091Completed

International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)

Role: collaborator

NCT05260879Not ApplicableCompleted

Potential Effectiveness of the Diabetes Prevention Program in the Peri-urban Area of Bamako, Mali

Role: lead

NCT04149106Phase 3Unknown

Seasonal Malaria Chemoprevention With Dihydroartemisin Piperaquin vs. Sulfadoxine-pyrimethamin+Amodiaquin

Role: lead

NCT05441800Unknown

Epidemiology and Clinical Characteristics of Emerging and Re-emerging Infectious Diseases With Epidemic Potential in Mali

Role: lead

NCT04149119Not ApplicableUnknown

Attractive Targeted Sugar Bait Trial in Mali

Role: lead

All 5 trials loaded